3C-FP

3C-FP
Clinical data
Other names4-(3-Fluoropropoxy)-3,5-dimethoxyamphetamine; 3,5-Dimethoxy-4-(3-fluoropropoxy)amphetamine; α-Methylfluoroproscaline; 3C-Fluoroproscaline
Routes of
administration
Oral
Drug classSerotonin receptor modulator; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen
ATC code
  • None
Pharmacokinetic data
Duration of action~8 hours
Identifiers
  • 1-[4-(3-fluoropropoxy)-3,5-dimethoxyphenyl]propan-2-amine
PubChem CID
ChemSpider
Chemical and physical data
FormulaC14H22FNO3
Molar mass271.332 g·mol−1
3D model (JSmol)
  • CC(CC1=CC(=C(C(=C1)OC)OCCCF)OC)N
  • InChI=1S/C14H22FNO3/c1-10(16)7-11-8-12(17-2)14(13(9-11)18-3)19-6-4-5-15/h8-10H,4-7,16H2,1-3H3
  • Key:AKWFBZJFCPKTRW-UHFFFAOYSA-N

3C-FP, also known as 4-(3-fluoropropoxy)-3,5-dimethoxyamphetamine or as α-methylfluoroproscaline (3C-fluoroproscaline), is a psychedelic drug of the phenethylamine, amphetamine, and 3C families related to TMA (3,4,5-TMA). It is the amphetamine (α-methyl) derivative of fluoroproscaline (FP).

According to Daniel Trachsel, 3C-FP's dose is 25 mg or more orally and its duration is approximately 8 hours. The specific effects of 3C-FP were not described.

The receptor interactions of 3C-FP have been studied. It shows affinity for the serotonin 5-HT2A and 5-HT2C receptors (Ki = 2,600–4,581 nM and 4,400 nM) and is a potent partial agonist of the serotonin 5-HT2A receptor (EC50Tooltip half-maximal effective concentration = 57 nM; EmaxTooltip maximal efficacy = 62%) but not of the serotonin 5-HT2B receptor (EC50 = >10,000 nM).

The chemical synthesis of 3C-FP has been described.

3C-FP was first described in the scientific literature by Trachsel in 2002. Subsequently, its pharmacology as well as its properties in humans were reported by Trachsel and colleagues in 2012, 2013, and 2021.

See also